Exploratory/Developmental Grants Phase II (R33)
The NIH R33 mechanism provides a second phase of funding for projects initiated under an R21 Exploratory/Developmental Grant, supporting continued development and proof-of-concept activities.
Eligibility Criteria:
-
Primary: Current R21 awardees demonstrating sufficient progress.
-
Exceptions: Certain initiatives may allow non-R21 recipients to apply if they can show equivalent milestones.
-
Applicant: Must be PD/PI of the parent R21; institutional and investigator eligibility per specific NOFO.
Award Information:
-
Instrument: Grant
-
Category: Research and Development
-
Mechanism Code: RP – Research Projects
-
Project Period & Budget: Defined by parent NOFO; funds support personnel, supplies, and other direct research costs.
-
Non-Renewable: Single phase II award.
Participating Institutes:
Applicants must fit one of the participating NIH Institutes’ missions. Current participants include:
-
NICHD, NCI, NCCIH, NEI, NHLBI
-
NIAMS, NIBIB, NIDCR, NIDDK, NIMH
-
NIA, NIAAA, NIDCD
-
ODS, ORWH
(Check the specific funding announcement for your institute.)
Application & Submission:
-
Mechanism: Follow parent R21 NOFO instructions for transitioning to R33.
-
Deadlines: Match R21 cutoff dates or as specified in the phase II NOFO.
-
Submission Portal: Grants.gov → eRA Commons.
-
Required Materials: Progress report on R21 aims, updated research plan, budget, biosketches, and institutional letters.
Resources & Contacts:
-
R21/R33 Parent FOAs: NIH Guide (search “PA-24-XXX R33”)
-
Staff Guidance: Consult the Scientific/Research contacts listed in the NOFO.
-
Admin Support: Your institution’s grants office or NIH eRA Help Desk.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023